Alivus Life Sciences Ltd.
ISIN: INE03Q201024 • Market Cap: ₹16,806 Cr
The 5-Pillar Quality Audit for Alivus Life Sciences Ltd.
Evaluated across Profitability, Financial Health, Historical Compounding, Valuation Safety, and Ownership Governance:
1. Profitability & Capital Efficiency
Weight: 25%Measures operating margins (32.3%), Return on Capital Employed (22.5%), and equity compounding (16.9%).
2. Financial Health & Solvency
Weight: 25%Debt-to-Equity is 0.00 with comfortable interest coverage and clean working capital.
3. Growth & Compounding Track Record
Weight: 20%Historical 3Y Sales CAGR (4.3%) and 3Y PAT CAGR (8.6%).
4. Valuation Multiple & Margin of Safety
Weight: 15%Trades at P/E of 27.87 vs PEG of 2.58 and Dividend Yield of 0.4%.
5. Ownership Quality & Governance
Weight: 15%Promoter holding stands at 74.9%, backed by 12.7% institutional ownership.
Key Fundamental Strengths
Superior Capital Efficiency (ROCE: 22.5%)
Alivus Life Sciences Ltd. generates exceptional return on capital employed of 22.5%, reflecting pricing power and competitive moat.
Fortress Balance Sheet (D/E: 0.00)
The company operates virtually debt-free, shielding net margins from interest rate cycles and monetary tightening.
Areas to Watch & Potential Risks
Topline Stagnation (3Y Sales CAGR: 4.3%)
Revenue growth has slowed below inflation rates, indicating cyclical demand slowdown or saturated core markets.
Sectoral & Macro Headwinds (Healthcare)
Subject to broader cyclical demand, raw material price shifts, and regulatory frameworks governing the Healthcare space.
Quantitative Strategy Eligibility
Checking ALIVUS against established Indian wealth creation frameworks:
Coffee Can Investing Framework
Fails 10%+ revenue growth or 15%+ minimum capital return benchmark over historical periods.
Quality Factor Screener (High RoIC + Low Debt)
Qualifies for Indian Quality Indices with overall score of 70/100 and clean gearing.
GARP / Value-Growth Blend
Valuation multiple or return metrics require further cyclical pullback.
Healthcare Sector Peer Comparison
Compare ALIVUS directly against top industry peers by market capitalization:
| Company | 5-Pillar Score | Market Cap | P/E | ROCE | D/E | Scorecard |
|---|---|---|---|---|---|---|
| Alivus Life Sciences Ltd. (ALIVUS)Current | 70/100 | ₹16,806 Cr | 27.87 | 22.5% | 0.00 | — |
| Sun Pharmaceutical Industries Ltd. (SUNPHARMA) | 77/100 | ₹4.55 Lakh Cr | 37.65 | 20.4% | 0.05 | View |
| Divi's Laboratories Ltd. (DIVISLAB) | 73/100 | ₹2.26 Lakh Cr | 77.37 | 19.4% | 0.00 | View |
| Torrent Pharmaceuticals Ltd. (TORNTPHARM) | 64/100 | ₹1.91 Lakh Cr | 87.43 | 9.5% | 1.76 | View |
| Apollo Hospitals Enterprise Ltd. (APOLLOHOSP) | 70/100 | ₹1.27 Lakh Cr | 60.55 | 19.1% | 0.62 | View |
| Cipla Ltd. (CIPLA) | 63/100 | ₹1.14 Lakh Cr | 33.94 | 16.1% | 0.01 | View |
Frequently Asked Questions: Alivus Life Sciences Ltd.
Q:What is the 5-Pillar Fundamental Score for Alivus Life Sciences Ltd. (ALIVUS)?
Alivus Life Sciences Ltd. has a RupeeTools Fundamental Score of 70/100, placing it in the 'Solid & Healthy' category. Its pillar scores are: Profitability (87/100), Financial Health (81/100), Growth (48/100), Valuation (50/100), and Ownership Quality (72/100).
Q:Is ALIVUS fundamentally strong for long-term investment?
Yes, ALIVUS exhibits solid fundamental strength with a 70/100 score, driven by a return on equity of 16.9% and a debt-to-equity ratio of 0.00.
Q:Does ALIVUS pass the Coffee Can Investing filter?
No. ALIVUS does not currently meet the strict 15% ROCE and 10% sustained topline compounding threshold mandated by the Coffee Can investing framework.
Q:How does ALIVUS compare against other Healthcare peers?
Within India's Healthcare sector, ALIVUS trades at a P/E of 27.87 and generates an ROCE of 22.5%. Compare its 5-Pillar score of 70/100 against top sector peers like Sun Pharmaceutical Industries Ltd. (77/100), Divi's Laboratories Ltd. (73/100).
Regulatory & SEBI Research Analyst Compliance Disclaimer:
This 5-pillar fundamental score is an automated quantitative health check generated purely from historical public financial statements, corporate filings, and exchange disclosures for educational and informational purposes only. It does NOT constitute investment advice, a stock recommendation, or a solicitation to buy or sell securities. RupeeTools is not a SEBI-registered Research Analyst. Please consult a SEBI-registered financial advisor before making investment decisions.